A Phase 1, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a highly selective NaV1.8 inhibitor, in Healthy Male Adults.

5 February 2021. doid: 10.1093/pm/pnab032

Hijma HJH, Siebenga PSP, de Kam MLM, Groeneveld GJGJ

To evaluate the analgesic potential, safety, tolerability and pharmacokinetics of VX-150, a pro-drug of a highly selective NaV1.8 inhibitor, in healthy subjects.